Genetic testing has become a pivotal tool in the early detection and prevention of breast cancer. As the number of breast cancer cases continues to rise worldwide, genetic mutations, often driven by lifestyle factors, have become a key focus in understanding cancer susceptibility. While the majority of breast cancer cases are sporadic, about 15% are linked to hereditary factors, with family history playing a significant role.
Dr. Sandip Bipte, a breast surgeon at P.D. Hinduja Hospital, highlights that BRCA1 and BRCA2 mutations are responsible for 70-80% of hereditary breast cancers. Detecting these gene mutations is essential for both prevention and treatment. Genetic testing, which can be done using blood, saliva, or tumor tissue samples, has advanced in recent years, enabling early identification of cancer risks in individuals with a family history of the disease or those diagnosed at a young age.
The benefits of genetic testing are twofold. First, it aids in making informed therapeutic decisions, particularly for patients who test positive for BRCA mutations. Second, it enables heightened surveillance, allowing for early detection of future cancers. For high-risk individuals, the implications are profound. A positive BRCA test can signal a 70-80% chance of developing breast cancer by the age of 80, far higher than in the general population. Preventive measures, such as prophylactic mastectomy, can reduce the risk of breast cancer by up to 98%.
Additionally, genetic testing is crucial in assessing the risk of ovarian cancer, which can be mitigated through preventive surgeries or new treatments targeting BRCA-positive patients. However, genetic testing should be used carefully, especially among younger populations. To ensure informed decision-making, experts recommend the involvement of genetic counseling teams throughout the process.
